# Integer Holdings Corp: Form 10-Q for the period ended Jun 30, 2017

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2017-08-02
- Accepted by EDGAR: Aug 2, 2017, 13:20 ET
- Period: 2017-06-30
- Accession: 0001114483-17-000020
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000111448317000020/itgr-2017063010q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000111448317000020/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 6 months, 2016-12-31 to 2017-06-30 | $708.1m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2017-04-01 to 2017-06-30 | $263.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2016-12-31 to 2017-06-30 | $517.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2017-04-01 to 2017-06-30 | $99.3m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2016-12-31 to 2017-06-30 | $190.5m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2017-04-01 to 2017-06-30 | $39.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2016-12-31 to 2017-06-30 | $79.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2017-04-01 to 2017-06-30 | $39.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2016-12-31 to 2017-06-30 | $66.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-04-01 to 2017-06-30 | $25.6m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2016-12-31 to 2017-06-30 | $54.5m | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-04-01 to 2017-06-30 | $1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2016-12-31 to 2017-06-30 | $1.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | $3.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2016-12-31 to 2017-06-30 | −$1.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | $0.09 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2016-12-31 to 2017-06-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-04-01 to 2017-06-30 | $0.10 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2016-12-31 to 2017-06-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-04-01 to 2017-06-30 | 31,982,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2016-12-31 to 2017-06-30 | 31,159,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2016-12-31 to 2017-06-30 | $77.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2016-12-31 to 2017-06-30 | $22.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2017-06-30 | $46.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-06-30 | $524.1m | us-gaap:AssetsCurrent |
| Total assets | at 2017-06-30 | $2.84bn | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $195.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-06-30 | $2.06bn | us-gaap:Liabilities |
| Long-term debt | at 2017-06-30 | $1.64bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-06-30 | $25.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2017-06-30 | $783.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 59,048 characters.

*This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the fiscal year ended December 30, 2016. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.*

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

- future sales, expenses, and profitability;
- future development and expected growth of our business and industry;
- our ability to execute our business model and our business strategy;
- our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets;
- our ability to remain in compliance with the financial covenants contained in the agreement governing our Senior Secured Credit Facilities; and
- projected capital expenditures.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: our high level of indebtedness, our inability to pay principal and interest on this high level of outstanding indebtedness or to remain in compliance with financial and other covenants under our Senior Secured Credit Facilities, and the risk that this high level of indebtedness limits our ability to invest in our business and overall financial flexibility; our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost savings and consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; product field actions or recalls; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate these acquired businesses, including Lake Region Medical, in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products; the timing, progress and ultimate success of pending regulatory actions and approvals; our inability to obtain licenses to key technology; regulatory changes, including health care reform, or consolidation in the healthcare industry; global economic factors, including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in other periodic filings with the SEC. Except as required by applicable law, the Company assumes no obligation to update forward-looking statements in this report whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

- 28 -

### Our Business

Integer Holdings Corporation is one of the largest medical device outsource (“MDO”) manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular and advanced surgical markets. We provide innovative, high-quality medical technologies that enhance the lives of patients worldwide. We also serve the non-medical power solutions market by developing batteries for high-end niche applications in the energy, military, and environmental markets.

On March 14, 2016, we completed the spin-off of a portion of our former QiG segment through a tax-free distribution of all of the shares of our QiG Group, LLC subsidiary to the stockholders of Integer on a pro rata basis (the “Spin-off”). Immediately prior to completion of the Spin-off, QiG Group, LLC was converted into a corporation organized under the laws of Delaware and changed its name to Nuvectra Corporation (“Nuvectra”). Our results include the financial and operating results of Nuvectra until the Spin-off on March 14, 2016.

As a result of our Lake Region Medical acquisition in 2015 and the Spin-off, during 2016 we reorganized our operations including our internal management and financial reporting structure. As a result of this reorganization, we reevaluated and revised our reportable business segments during the fourth quarter of 2016 and began to disclose two reportable segments: (1) Medical and (2) Non-Medical. Prior period amounts in this report have been reclassified to conform to the new segment reporting presentation.

### Our Acquisitions

With the acquisition of Lake Region Medical, our main strategic priorities over the next two years include, among others, the integration of the legacy Greatbatch, Inc. and Lake Region Medical companies, driving integration synergies, and paying down our outstanding debt. Our acquisition focus, if any, will be primarily directed at smaller “bolt-on” or adjacent acquisition opportunities that have a strategic fit with our existing core businesses, particularly opportunities that support our enterprise strategy and enhance the value proposition of our product offerings.

### Our Customers

Our products are designed to provide reliable, long-lasting solutions that meet the evolving requirements and needs of our customers. The nature and extent of our selling relationships with each customer are different in terms of breadth of products purchased, purchased product volumes, length of contractual commitment, ordering patterns, inventory management, and selling prices.

Our Medical customers include large multi-national medical device original equipment manufacturers (“OEMs”) and their subsidiaries such as Abbott Labs, Biotronik, Boehringer Ingelheim, Boston Scientific, Cardinal Health, Johnson & Johnson, LivaNova, Medtronic, Nevro Corp., Philips Healthcare, Smith & Nephew, Stryker, and Zimmer Biomet. For the six months ended June 30, 2017, Abbott Labs, Boston Scientific, Johnson & Johnson, and Medtronic collectively accounted for approximately 56% of our total sales. We believe that the diversification of our sales among the various subsidiaries and market segments with those four customers reduces our exposure to negative developments with any one customer. The loss of a significant amount of business from any of these four customers or a further consolidation of such customers could have a material adverse affect on our financial condition and results of operations.

Our Non-Medical customers include large multi-national OEMs and their subsidiaries serving the energy, military and environmental services markets such as Halliburton, Teledyne Technologies and Weatherford International.

- 29 -

### Financial Overview

Net income for the second quarter (“QTD”) and first six months (“YTD”) of 2017 was $3.0 million, or $0.09 per diluted share, and a net loss of $1.3 million, or $0.04 per diluted share, respectively, compared to net losses of $0.8 million, or $0.03 per diluted share, and $13.4 million, or $0.44 per diluted share, for the second quarter and first six months of 2016, respectively. These year over year variances are primarily the result of the following:

- Sales for the second quarter and first six months of 2017 increased 4% for each period. In comparison to the prior year periods, foreign currency exchange rates decreased sales by approximately $1.2 million and $2.6 million for the second quarter and first six months of 2017, respectively, and the Spin-off decreased sales by $1.2 million for the first six months of 2017. Excluding these amounts, organic sales for the second quarter and first six months of 2017 each increased 5%, primarily driven by market growth, new business wins, as well as lower comparables versus 2016 in our Cardio & Vascular and Advanced Surgical, Orthopedics & Portable Medical product lines due to the disruption of supply caused by the transfer of certain product lines throughout 2016;
- Gross profit for the second quarter and first six months of 2017 increased $3.2 million and $3.0 million, respectively, primarily due to the increase in sales discussed above;
- Operating expenses for the second quarter and first six months of 2017 were lower by $7.2 million and $22.9 million, respectively, primarily due to the results of Nuvectra not being included after the Spin-off ($4.7 million YTD), lower consolidation and integration charges ($9.4 million QTD, $18.8 million YTD), and various efficiencies and synergies gained as a result of our integration and consolidation initiatives partially offset by higher performance based compensation ($1.4 million QTD and YTD);
- Interest expense for the second quarter and first six months of 2017 declined $2.3 million and $1.0 million, respectively, primarily due to the amendment of our Term Loan B Facility in March 2017, which lowered the interest rate by 75 basis points, as well as the repayment of $68.8 million of debt during the first six months of 2017. These reductions were partially offset by the accelerated write-off of deferred fees and original issue discount due to the accelerated pay down of debt during the first half of 2017 ($0.9 million QTD, $2.5 million YTD); and
- Other (income) loss, net - higher losses on our cost and equity method investments ($4.3 million QTD, $6.0 million YTD) and higher foreign currency exchange rate losses ($5.0 million QTD, $8.8 million YTD) driven by the remeasurement of intercompany loans and the weakening of the U.S. dollar relative to the Euro during the first half of 2017, which are primarily non-cash in nature.

### Use of Non-GAAP Financial Information

We prepare our condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we consistently report and discuss in our earnings releases and investor presentations adjusted net income, adjusted earnings per diluted share, earnings before interest, taxes, depreciation, and amortization (“EBITDA”), adjusted EBITDA and organic sales growth rates. Adjusted net income and adjusted earnings per diluted share consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition and integration related charges and expenses, (ii) amortization of intangible assets including inventory step-up amortization, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain litigation expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) gain/loss on cost and equity method investments, (ix) extinguishment of debt charges, (x) the income tax (benefit) related to these adjustments and (xi) certain tax items that are outside the normal provision for the period. Adjusted earnings per diluted share are calculated by dividing adjusted net income by diluted weighted average shares outstanding. Adjusted EBITDA consists of GAAP net income (loss) plus (i) the same adjustments as listed above except for items (x) and (xi), (ii) GAAP stock-based compensation, interest expense, and depreciation, (iii) GAAP provision (benefit) for income taxes and (iv) cash gains received from cost and equity method investments during the period. To calculate organic sales growth rates, which exclude the impact of changes in foreign currency exchange rates, as well as the impact of any acquisitions or divestitures of product lines on sales growth rates, we convert current period sales from local currency to U.S. dollars using the previous periods foreign currency exchange rates and exclude the amount of sales acquired/divested during the period from the current/previous period amounts, respectively. We believe that the presentation of adjusted net income, adjusted diluted earnings per share, EBITDA, adjusted EBITDA, and organic sales growth rates provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations.

- 30 -

A reconciliation of GAAP net income (loss) and diluted earnings (loss) per share (“EPS”) to adjusted amounts is as follows (in thousands, except per share amounts):

|  | Three Months Ended June 30, 2017 Pre-Tax | Net Income | Per Diluted Share | July 1, 2016 Pre-Tax | Net Income (Loss) | Per Diluted Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| As reported (GAAP) | $4,116 | $2,990 | $0.09 | $687 | $(770) | $(0.03) |
| Adjustments: |  |  |  |  |  |  |
| Amortization of intangibles(a) | 11,046 | 7,815 | 0.24 | 9,514 | 6,732 | 0.22 |
| IP related litigation (SG&A)(a)(b) | 915 | 595 | 0.02 | 285 | 185 | 0.01 |
| Consolidation and optimization expenses (OOE)(a)(c) | 2,832 | 2,093 | 0.07 | 7,376 | 5,975 | 0.19 |
| Acquisition and integration expenses (OOE)(a)(d) | 2,970 | 2,037 | 0.06 | 7,859 | 5,145 | 0.16 |
| Asset dispositions, severance and other (OOE)(a)(e) | 1,118 | 727 | 0.02 | 259 | 197 | 0.01 |
| Loss on cost and equity method investments, net(a) | 4,427 | 2,877 | 0.09 | 124 | 81 | — |
| Loss on extinguishment of debt(a)(f) | 935 | 608 | 0.02 | — | — | — |
| Taxes(a) | (8,617) | — | — | (8,559) | — | — |
| Adjusted (Non-GAAP) |  | $19,742 | $0.62 |  | $17,545 | $0.56 |
| Diluted weighted average shares for adjusted EPS(h) |  | 31,982 |  |  | 31,228 |  |

|  | Six Months Ended June 30, 2017 Pre-Tax | Net Income (Loss) | Per Diluted Share | July 1, 2016 Pre-Tax | Net Income (Loss) | Per Diluted Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| As reported (GAAP) | $(79) | $(1,349) | $(0.04) | $(12,075) | $(13,430) | $(0.44) |
| Adjustments: |  |  |  |  |  |  |
| Amortization of intangibles(a) | 22,024 | 15,561 | 0.49 | 18,978 | 13,423 | 0.43 |
| IP related litigation (SG&A)(a)(b) | 1,292 | 840 | 0.03 | 2,192 | 1,425 | 0.05 |
| Consolidation and optimization expenses (OOE)(a)(c) | 5,227 | 3,992 | 0.13 | 14,025 | 11,289 | 0.36 |
| Acquisition and integration expenses (OOE)(a)(d) | 7,790 | 5,170 | 0.16 | 17,824 | 11,656 | 0.37 |
| Asset dispositions, severance and other (OOE)(a)(e) | 5,674 | 3,684 | 0.12 | 4,785 | 4,423 | 0.14 |
| (Gain) loss on cost and equity method investments, net(a) | 4,825 | 3,136 | 0.10 | (1,177) | (765) | (0.02) |
| Loss on extinguishment of debt(a)(f) | 2,494 | 1,621 | 0.05 | — | — | — |
| Nuvectra results prior to Spin-off (a)(g) | — | — | — | 4,037 | 2,624 | 0.08 |
| Taxes(a) | (16,592) | — | — | (17,944) | — | — |
| Adjusted (Non-GAAP) |  | $32,655 | $1.03 |  | $30,645 | $0.98 |
| Diluted weighted average shares for adjusted EPS(h) |  | 31,833 |  |  | 31,257 |  |

(a) The difference between pre-tax and net income (loss) amounts is the estimated tax impact related to the respective adjustment. Net income amounts are computed using a 35% U.S. tax rate, and the statutory tax rates in Mexico, Germany, France, Netherlands, Uruguay, Ireland and Switzerland, as adjusted for the existence of net operating losses. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

(b) In 2013, we filed suit against AVX Corporation alleging they were infringing our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, we are excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and a federal jury awarded the Company $37.5 million in damages. This finding is subject to post-trial proceedings currently scheduled to be held in August 2017. To date, no gains have been recognized in connection with this litigation.

- 31 -

(c) During 2017 and 2016, we incurred costs primarily related to the transfer of our Beaverton, OR portable medical and Plymouth, MN vascular manufacturing operations to Tijuana, Mexico, the closure of our Arvada, CO, site and the consolidation of our two Galway, Ireland sites. In addition, 2017 costs also include expenses related to the closure of our Clarence, NY facility.

(d) Reflects acquisition and integration costs related to the acquisition of Lake Region Medical, which was acquired in October 2015.

(e) Amounts for the second quarter of 2017 include approximately $0.6 million ($5.3 million YTD) of expense related to our CEO, CFO and Chief Human Resources Officer transitions. Costs for 2016 primarily include legal and professional fees incurred in connection with the Spin-off, which was completed in March 2016.

(f) Represents debt extinguishment charges in connection with pre-payments made on our Term Loan B Facility during 2017, which are included in Interest Expense, Net.

(g) Represents the results of Nuvectra prior to the Spin-off on March 14, 2016.

(h) The diluted weighted average shares for adjusted EPS for the six months ended June 30, 2017 include 674,000 of potentially dilutive shares not included in the computation of diluted weighted average common shares for GAAP diluted EPS purpose because their effect would have been anti-dilutive given the Company’s net loss in that period. The diluted weighted average shares for adjusted EPS for the three and six months ended July 1, 2016 include 461,000 and 514,000, respectively, of potentially dilutive shares not included in the computation of diluted weighted average common shares for GAAP diluted EPS purposes because their effect would have been anti-dilutive given the Company’s net loss in those periods.

Adjusted diluted EPS of $0.62 and $1.03 per share for the second quarter and first six months of 2017, respectively, increased 11% and 5%, respectively, in comparison to the prior year periods. This was a result of the benefit of our increased sales and the various efficiencies and synergies gained from our integration and consolidation initiatives, partially offset by higher foreign currency exchange rate losses. The increase in losses from foreign exchange rate changes was $5.0 million ($4.0 million net of tax, $0.12 per diluted share) and $8.8 million ($7.1 million net of tax, $0.22 per diluted share) for the second quarter and first six months of 2017, respectively, in comparison to the prior year periods.

A reconciliation of GAAP net income (loss) to EBITDA and adjusted EBITDA is as follows (dollars in thousands):

|  | Three Months Ended June 30, 2017 | July 1, 2016 | Six Months Ended June 30, 2017 | July 1, 2016 |
| --- | ---: | ---: | ---: | ---: |
| Net income (loss) (GAAP) | $2,990 | $(770) | $(1,349) | $(13,430) |
| Interest expense | 25,647 | 27,908 | 54,540 | 55,525 |
| Provision for income taxes | 1,126 | 1,457 | 1,270 | 1,355 |
| Depreciation | 13,813 | 13,121 | 27,441 | 26,070 |
| Amortization | 11,046 | 9,514 | 22,024 | 18,978 |
| EBITDA | 54,622 | 51,230 | 103,926 | 88,498 |
| IP related litigation | 915 | 285 | 1,292 | 2,192 |
| Stock-based compensation (excluding OOE) | 3,251 | 1,794 | 5,657 | 3,823 |
| Consolidation and optimization expenses | 2,832 | 7,376 | 5,227 | 14,025 |
| Acquisition and integration expenses | 2,970 | 7,859 | 7,790 | 17,824 |
| Asset dispositions, severance and other | 1,118 | 259 | 5,674 | 4,785 |
| Noncash (gain) loss on cost and equity method investments | 4,427 | 124 | 4,825 | (515) |
| Nuvectra results prior to Spin-off | — | — | — | 3,665 |
| Adjusted EBITDA (Non-GAAP) | $70,135 | $68,927 | $134,391 | $134,297 |

- 32 -

### 2017 Outlook

Our current full-year 2017 outlook is as follows (in millions, except for per share amounts):

| Sales Earnings per Diluted Share(a) | GAAP As Reported $1,400 to $1,430 $0.60 to $1.00 | Non-GAAP(b) Growth Adjusted Growth 1% to 3% $1,400 to $1,430 1% to 3% Favorable $2.55 - $2.95 (5)% to 10% |
| --- | --- | ---: |
| Cash Flow from Operations | ~$150 | 42% |

(a) Except as described below, further reconciliations by line item to the closest corresponding GAAP financial measures for Adjusted EPS, included in our “2017 Outlook” above, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from this non-GAAP financial measure.

(b) Adjusted EPS for 2017 is expected to consist of GAAP Net Income and EPS, excluding items such as intangible amortization ($44 million), IP related litigation costs, and consolidation, acquisition, integration, asset disposition and write-down charges, and loss on extinguishment of debt totaling approximately $90 million. The after-tax impact of these items is estimated to be approximately $62 million, or approximately $1.95 per diluted share.

### Our CEO’s View

Another quarter of solid sales growth gives us confidence that we are back on an annual growth trajectory. We have had four quarters in a row of strong cash generation and even stronger debt repayment, which demonstrates our commitment to deleveraging. We are making good progress transitioning our business back to an annual growth trajectory. We are the market leader in Medical Device Outsource manufacturing, we have unrivaled capabilities to serve our customers’ needs - whether an engineered component or a complete device, to anything in between. Our innovative design and manufacturing capabilities, our global footprint and scalability, our high-quality, and our customer focus enable us to deliver more for our customers. As we execute our strategy and realize our vision, we expect to deliver sales growth that is above the market growth rate, we expect to accelerate our EBITDA and cash flow growth and we desire to earn a valuation premium for our shareholders.

### Cost Savings and Consolidation Efforts

In 2017 and 2016, we recorded charges in Other Operating Expenses, Net related to various cost savings and consolidation initiatives. These initiatives were undertaken to improve our operational efficiencies and profitability, the most significant of which are as follows (dollars in millions):

| Initiative | Expected Expense | Expected Capital | Expected Benefit to Operating Income(a) | Expected Completion |
| --- | --- | --- | --- | --- |
| Investments in capacity and capabilities | $53 - $55 | $24 - $25 | \> $20 | 2017 |
| Lake Region Medical consolidations | $20 - $25 | $5 - $6 | $12 - $13 | 2018 |

(a) Represents the annual benefit to our operating income expected to be realized from these initiatives through cost savings and/or increased capacity. These benefits will be phased in over time as the various initiatives are completed, and some of which are already included in our current period results.

See Note 9 “Other Operating Expenses, Net” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the timing, cash flow impact and amount of future expenditures for these initiatives. We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. Future charges are expected to be incurred as we seek to create an optimized manufacturing footprint, leveraging our increased scale and product capabilities while also supporting the needs of our customers. Our efforts will include:

- potential manufacturing consolidations;
- continuous improvement and productivity initiatives;
- direct material and indirect expense savings opportunities; and
- the establishment of centers of excellence around the world.
- 33 -

### Our Financial Results

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. For 52-week years, each quarter contains 13 weeks. The second quarter and first six months of 2017 and 2016 ended on June 30, and July 1, respectively, and each contained 13 weeks and 26 weeks, respectively.

During the first quarter of 2017, we revised the method used to present sales by product line in order to align the legacy Greatbatch and Lake Region Medical methodologies. We believe the revised presentation will provide improved reporting and better transparency into the operational results of our business and markets. Prior period amounts have been reclassified to conform to the new product line sales reporting presentation.

The following tables present selected financial information derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share):

| Medical Sales: | Three Months Ended June 30, 2017 | July 1, 2016 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio & Vascular | $132,231 | $122,253 | $9,978 | 8.2% |
| Cardiac & Neuromodulation | 106,185 | 106,919 | (734) | (0.7)% |
| Advanced Surgical, Orthopedics & Portable Medical | 108,560 | 109,391 | (831) | (0.8)% |
| Total Medical Sales | 346,976 | 338,563 | 8,413 | 2.5% |
| **Non-Medical** | 15,743 | 9,819 | 5,924 | 60.3% |
| Total Sales | 362,719 | 348,382 | 14,337 | 4.1% |
| Cost of sales | 263,447 | 252,351 | 11,096 | 4.4% |
| Gross profit | 99,272 | 96,031 | 3,241 | 3.4% |
| Gross profit as a % of sales | 27.4% | 27.6% |  |  |
| Selling, general and administrative expenses (“SG&A”) | 39,724 | 37,628 | 2,096 | 5.6% |
| SG&A as a % of sales | 11.0% | 10.8% |  |  |
| Research, development and engineering costs, net (“RD&E”) | 12,889 | 13,640 | (751) | (5.5)% |
| RD&E as a % of sales | 3.6% | 3.9% |  |  |
| Other operating expenses, net | 6,920 | 15,494 | (8,574) | (55.3)% |
| Operating income | 39,739 | 29,269 | 10,470 | 26.3% |
| Operating margin | 11.0% | 8.4% |  |  |
| Interest expense, net | 25,647 | 27,908 | (2,261) | (8.1)% |
| Other loss, net | 9,976 | 674 | 9,302 | NM |
| Income before provision for income taxes | 4,116 | 687 | 3,429 | NM |
| Provision for income taxes | 1,126 | 1,457 | (331) | (22.7)% |
| Effective tax rate | 27.4% | 0.8% |  |  |
| Net income (loss) | $2,990 | $(770) | $3,760 | NM |
| Net income (loss) as a % of sales | 0.8% | (0.2)% |  |  |
| Diluted earnings (loss) per share | $0.09 | $(0.03) | $0.12 | NM |

- 34 -

### MANAGEMENT'S DISCUSSION AND ANALYSIS

| Medical Sales: | Six Months Ended June 30, 2017 | July 1, 2016 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio & Vascular | $257,339 | $235,924 | $21,415 | 9.1% |
| Cardiac & Neuromodulation | 209,998 | 215,452 | (5,454) | (2.5)% |
| Advanced Surgical, Orthopedics & Portable Medical | 213,706 | 207,753 | 5,953 | 2.9% |
| Total Medical Sales | 681,043 | 659,129 | 21,914 | 3.3% |
| **Non-Medical** | 27,089 | 21,491 | 5,598 | 26.0% |
| Total Sales | 708,132 | 680,620 | 27,512 | 4.0% |
| Cost of sales | 517,634 | 493,121 | 24,513 | 5.0% |
| Gross profit | 190,498 | 187,499 | 2,999 | 1.6% |
| Gross profit as a % of sales | 26.9% | 27.5% |  |  |
| SG&A | 79,223 | 79,516 | (293) | (0.4)% |
| SG&A as a % of sales | 11.2% | 11.7% |  |  |
| RD&E | 26,300 | 30,946 | (4,646) | (15.0)% |
| RD&E as a % of sales | 3.7% | 4.5% |  |  |
| Other operating expenses, net | 18,691 | 36,634 | (17,943) | (49.0)% |
| Operating income | 66,284 | 40,403 | 25,881 | 64.1% |
| Operating margin | 9.4% | 5.9% |  |  |
| Interest expense, net | 54,540 | 55,525 | (985) | (1.8)% |
| Other (income) loss, net | 11,823 | (3,047) | 14,870 | NM |
| Loss before provision for income taxes | (79) | (12,075) | 11,996 | (99.3)% |
| Provision for income taxes | 1,270 | 1,355 | (85) | (6.3)% |
| Effective tax rate | NM | NM |  |  |
| Net loss | $(1,349) | $(13,430) | $12,081 | (90.0)% |
| Net loss as a % of sales | (0.2)% | (2.0)% |  |  |
| Diluted loss per share | $(0.04) | $(0.44) | $0.40 | (90.9)% |

NM Calculated amount not meaningful

- 35 -

### Product Line Sales Highlights

For the second quarter and first six months of 2017, Cardio & Vascular sales increased $10.0 million, or 8%, and $21.4 million, or 9%, respectively, versus the comparable 2016 periods. These increases were primarily attributable to market growth and new business wins, as well as lower comparables in the first quarter of 2016 due to the disruption of supply caused by the transfer of our catheter and introducer operations from our Plymouth, MN facility to our Tijuana, Mexico facility, which occurred throughout 2016. During the second quarter and first six months of 2017, price and foreign currency exchange rate fluctuations did not materially impact our Cardio & Vascular sales in comparison to the same periods of 2016.

For the second quarter and first six months of 2017, Cardiac & Neuromodulation sales decreased $0.7 million, or 1% and $5.5 million, or 3%, respectively, versus the comparable 2016 periods. Approximately $1.2 million of the year-to-date decrease was a result of the Spin-off of Nuvectra in the first quarter of 2016. Foreign currency exchange rate fluctuations did not have a material impact on Cardiac & Neuromodulation sales during the second quarter and first six months of 2017 in comparison to the same periods of 2016. For the second quarter and first six months of 2017, organic Cardiac & Neuromodulation sales, which excludes the impact of the Spin-off and currency exchange rate fluctuations, decreased 1% and 2%, respectively. These decreases were primarily the result of a customer specified supplier delay during the first quarter of 2017 within our Neuromodulation product line, which was resolved during the second quarter. Additionally, during the second quarter and first six months of 2017, price concessions to our larger OEM customers reduced Cardiac & Neuromodulation sales by approximately $3 million and $4 million, respectively, in comparison to the same periods of 2016. Partially offsetting these decreases was an increase in cardiac rhythm management sales, which has begun to rebound from the market disruptions experienced in 2016.

For the second quarter and first six months of 2017, Advanced Surgical, Orthopedics & Portable Medical sales decreased $0.8 million, or 1%, and increased $6.0 million, or 3%, respectively, versus the comparable 2016 periods. Foreign currency exchange rate fluctuations reduced second quarter and first six months of 2017 sales by approximately $1 million and $2 million, respectively, in comparison to the 2016 periods due to the stronger U.S. dollar relative to the Euro on an average basis during those periods. For the second quarter and first six months of 2017, organic Advanced Surgical, Orthopedics & Portable Medical sales, which excludes the impact of foreign currency exchange rate fluctuations, increased 0.1% and 4%, respectively, in comparison to the respective 2016 periods. The year-to-date increase was primarily due to advanced surgical market growth and lower comparables versus the first quarter of 2016 due to the disruption of supply caused by the transfer of our portable medical operations from our Beaverton, OR facility to our Tijuana, Mexico facility, which occurred throughout 2016. For the second quarter and first six months of 2017, price concessions to our larger OEM customers reduced Advanced Surgical, Orthopedics & Portable Medical sales by approximately $1 million and $2 million, respectively, in comparison to the same periods of 2016.

For the second quarter and first six months of 2017, Non-Medical sales increased $5.9 million, or 60%, and $5.6 million, or 26%, respectively, versus the comparable 2016 periods. These increases were primarily driven by continued recovery in the energy markets, as well as, new business wins and market share gains. Foreign currency exchange rates and price fluctuations did not have a material impact on Non-Medical sales during the second quarter and first six months of 2017 in comparison to the same periods of 2016.

- 36 -

### Gross Profit

Changes to gross profit as a percentage of sales (“Gross Margin”) from the prior year were due to the following:

|  | Change From Prior Year Three Months | Six Months |
| --- | ---: | ---: |
| Price(a) | (1.0)% | (1.1)% |
| Mix(b) | 0.2 | (0.1) |
| Incentive compensation(c) | (0.6) | (0.4) |
| Production efficiencies and volume(d) | 1.2 | 1.0 |
| Total percentage point change to gross profit as a percentage of sales | (0.2)% | (0.6)% |

(a) Our Gross Margin for 2017 has been negatively impacted by price concessions given to our larger OEM customers in return for long-term volume commitments.

(b) Our Gross Margin for the first six months of 2017 has been negatively impacted by a higher mix of sales of lower margin products. Our Gross Margin for the second quarter of 2017 benefited from a higher mix of sales of higher margin products.

(c) Amounts represent the impact to our Gross Margin attributable to our cash and stock incentive programs. Performance-based compensation is accrued based upon actual results achieved.

(d) Represents various increases and decreases to our Gross Margin. Overall, our Gross Margin for 2017 has been positively impacted by production efficiencies and synergies gained as a result of our integration and consolidation initiatives as well as higher volumes in comparison to the respective 2016 period.

### SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  | Change From Prior Year Three Months | Six Months |
| --- | ---: | ---: |
| Nuvectra SG&A(a) | $— | $(1,913) |
| Legal expenses(b) | 1,025 | (446) |
| Intangible asset amortization(c) | 1,676 | 3,298 |
| Incentive compensation programs(d) | 954 | 1,107 |
| Other(e) | (1,559) | (2,339) |
| Net increase (decrease) in SG&A Expenses | $2,096 | $(293) |

(a) Amount represents the impact to our SG&A related to the over-head costs divested as a result of the Spin-off of Nuvectra in March 2016.

(b) Amounts represent the change in legal costs compared to the prior year period. These variances were primarily due to the timing of legal expenses incurred related to our on-going patent infringement case. Refer to Note 11 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for information related to this patent infringement litigation.

(c) Amounts represent the increase in intangible asset amortization (i.e. customer list), which is amortized based upon the forecasted cash flows at the time of acquisition for the respective asset.

(d) Amounts represent the impact to our SG&A attributable to our cash and stock incentive programs. Performance-based compensation is accrued based upon actual results achieved.

(e) Represents various increases and decreases to our SG&A. Overall, our SG&A for 2017 has been positively impacted by efficiencies and synergies gained as a result of our integration and consolidation initiatives.

- 37 -

### RD&E Expenses, Net

Changes to RD&E expenses from the prior year were due to the following (in thousands):

|  | Change From Prior Year Three Months | Six Months |
| --- | ---: | ---: |
| Nuvectra RD&E(a) | $— | $(2,830) |
| Customer cost reimbursements(b) | 301 | (409) |
| Other(c) | (1,052) | (1,407) |
| Net decrease in RD&E Expenses, Net | $(751) | $(4,646) |

(a) Amount represents the impact to our RD&E related to the divested costs as a result of the Spin-off of Nuvectra in March 2016.

(b) Amount represents the change in customer cost reimbursements from the prior year. Customer cost reimbursements vary from period to period depending on the timing of achievement of project milestones.

(c) Amount represents various efficiencies and synergies gained as a result of our integration and consolidation initiatives.

### Other Operating Expenses, Net

Other Operating Expenses, Net is comprised of the following (in thousands):

|  | Three Months Ended June 30, 2017 | July 1, 2016 | Six Months Ended June 30, 2017 | July 1, 2016 |
| --- | ---: | ---: | ---: | ---: |
| Investments in capacity and capabilities(a) | $1,275 | $5,126 | $2,865 | $9,279 |
| Lake Region Medical consolidations(a) | 1,461 | 2,088 | 2,167 | 4,447 |
| Acquisition and integration costs(b) | 2,970 | 7,859 | 7,790 | 17,824 |
| Asset dispositions, severance and other(c) | 1,118 | 259 | 5,674 | 4,785 |
| Other consolidation and optimization initiatives | 96 | 162 | 195 | 299 |
| Total other operating expenses, net | $6,920 | $15,494 | $18,691 | $36,634 |

(a) Refer to “Cost Savings and Consolidation Efforts” section of this Item and Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for disclosures related to the timing and level of remaining expenditures for these initiatives.

(b) During the second quarter and first six months of 2017 and 2016, we incurred costs related to the acquisition of Lake Region Medical, consisting primarily of professional, consulting, severance, retention, relocation, and travel costs. In addition, the second quarter and first six months of 2016 includes change-in-control payments to former Lake Region Medical executives. Refer to Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for disclosures related to the timing and level of remaining expenditures for acquisition and integration costs.

(c) The second quarter and first six months of 2017 amounts include approximately $0.6 million and $5.3 million, respectively, in expense related to our CEO, CFO and Chief Human Resources Officer transitions. The 2016 amounts primarily include legal and professional costs incurred in connection with the Spin-off.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. Other Operating Expenses, Net for 2017 are expected to be approximately $25 million to $35 million.

- 38 -

### Interest Expense, Net

Interest Expense, Net for the three and six months ended June 30, 2017 was $25.6 million and $54.5 million, respectively, compared to $27.9 million and $55.5 million for the three and six months ended July 1, 2016. The weighted average interest rates paid on all outstanding borrowings for the three and six months ended June 30, 2017 were 5.28% and 5.53%, respectively, compared to 5.75% for the comparable periods in 2016. The lower weighted average interest rates paid in 2017 were primarily due to our amending our Senior Secured Credit Facilities during March of 2017, which resulted in a 75 basis point reduction to the applicable interest rate margins of our TLB facility, partially offset by the increase in the LIBOR rate during 2017. Cash interest expense decreased $3.3 million and $3.6 million for the three and six months ended June 30, 2017, respectively, when compared to the same periods in 2016, primarily due to the previously mentioned rate reduction combined with lower outstanding debt balances due to the repayment of debt over the last year. Non-cash interest expense (i.e. deferred fee and discount amortization) increased $1.0 million and $2.7 million for the three and six months ended June 30, 2017, respectively, when compared to the same periods in 2016, primarily attributable to the accelerated write-off (losses from extinguishment of debt) of deferred fees and discounts due to prepayments of a portion of our TLB Facility during the first and second quarters of 2017. We recognized losses from extinguishment of debt during the three and six months ended June 30, 2017 of $0.9 million and $2.5 million, respectively. We have repaid $68.8 million of debt during the first six months of 2017, including $39.7 million during the second quarter. See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

### Other (Income) Loss, Net

Other (Income) Loss, Net for the three and six months ended June 30, 2017 was a loss of $10.0 million and $11.8 million, respectively, compared to a loss of $0.7 million and income of $3.0 million for the three and six months ended July 1, 2016, respectively. Other (Income) Loss, Net is primarily comprised of income (loss) on our cost and equity method investments and the impact of foreign currency exchange rates on transactions denominated in foreign currencies.

Other (Income) Loss, Net for the three and six months ended June 30, 2017 includes net losses realized on our cost and equity method investments of $4.4 million and $4.8 million, respectively, compared to a net loss of $0.1 million and net gains of $1.2 million for the three and six months ended July 1, 2016, respectively. During the second quarter of 2017, we recognized a $5.0 million impairment charge on one of our cost method investments. These investments are in start-up research and development companies whose fair value is highly subjective in nature and could be subject to significant fluctuations in the future that could result in material gains or losses. See Note 14 “Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our cost and equity method investments.

The impact of foreign currency exchange rates on transactions denominated in foreign currencies included in Other (Income) Loss, Net for the three and six months ended June 30, 2017 was a loss of $5.5 million and $7.0 million, respectively, compared to a loss of $0.6 million and a gain of $1.8 million for the three and six months ended July 1, 2016, respectively. The losses in 2017 were primarily driven by the impact of the weakening U.S. dollar relative to the Euro on our inter-company loans and are primarily non-cash in nature. We continually reevaluate our foreign currency exposures and take steps to mitigate these risks. However, fluctuations in foreign currency exchange rates could have a significant impact, positive or negative, on our financial results in the future.

### Provision for Income Taxes

We recognized income tax expense of $1.1 million for the second quarter of 2017 on $4.1 million of pre-tax income compared to income tax expense of $1.5 million on $0.7 million of pre-tax income for the same period of 2016. The income tax expense for the first six months of 2017 was $1.3 million on a pre-tax loss of $0.1 million compared to $1.4 million on a pre-tax loss of $12.1 million for the same period of 2016. The effective tax rate for the second quarter and first six months of 2017 includes $0.4 million and $1.3 million, respectively, of discrete tax charges primarily related to stock based compensation expense in accordance with new guidance under Accounting Standards Update (“ASU”) 2016-09 and the taxation of currency gain and losses arising from qualified business units (e.g., Branches) that operate in a currency other than the currency of their owner, in accordance with new guidance under temporary regulations and Internal Revenue Code Section 987. The effective tax rate for the second quarter and first six months of 2016 includes discrete tax benefits of $0.3 million and discrete tax charges of $1.3 million, respectively, primarily related to return to provision adjustments and non-deductible Lake Region Medical and Spin-off related transaction costs, respectively.

- 39 -

We expect there to be continued volatility of our effective tax rate due to several factors including: changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. We continuously evaluate and currently have various tax planning initiatives in place that are aimed at reducing our effective tax rate over the long-term.

Our worldwide effective tax rate is expected to be approximately 10% for 2017, excluding discrete items. The difference between our effective tax rate and the U.S. federal statutory income tax rate in the current year is primarily attributable to our overall lower effective tax rate in the foreign jurisdictions in which we operate and where our foreign earnings are derived. The lower tax rate jurisdictions in which we operate and the respective statutory tax rate for each respective jurisdiction include Switzerland (22%), Mexico (30%), Uruguay (25%), and Ireland (12.5%). In addition, we currently have a tax holiday in Malaysia through April 2018, with a potential extension through April 2023 if certain conditions are met. While we are not currently aware of any material trends in these jurisdictions that are likely to impact our current or future tax expense, our future effective tax rates could be adversely affected by earnings being lower than anticipated in countries where we have lower effective tax rates and higher than anticipated in countries where we have higher effective tax rates, or by changes in tax laws or regulations. We regularly assess any significant exposure associated with increases in tax rates in international jurisdictions and adjustments are made as events occur that warrant adjustment to our tax provisions. Our 2017 blended effective tax rate on foreign earnings is currently estimated to be approximately 21%. The foreign rate differential reduces our worldwide effective tax rate by approximately 20% as compared to the U.S. statutory federal income tax rate. For the year, we expect to have positive income before taxes in our foreign jurisdictions but losses before taxes in U.S jurisdictions due to our large amount of Other Operating Expenses, Net and Interest Expense, Net.

### Liquidity and Capital Resources

*(dollars in thousands)*

|  | June 30, 2017 | December 30, 2016 |
| --- | ---: | ---: |
| Cash and cash equivalents | $46,533 | $52,116 |
| Working capital | 328,144 | 332,087 |
| Current ratio | 2.67 | 2.79 |

Cash and cash equivalents at June 30, 2017 decreased by $5.6 million from year-end as any excess cash flow from operations was used to pay down our debt. Working capital decreased $3.9 million from December 30, 2016 due to the Company’s strategic initiatives to reduce working capital in order to generate cash to pay down debt.

At June 30, 2017, approximately $22.4 million of the Company's $46.5 million of cash and cash equivalents resided in jurisdictions outside the United States. It is the Company's practice to use available cash in the United States to pay down its Senior Secured Credit Facilities in order to minimize total interest expense. Repatriation of funds residing in jurisdictions located outside the United States to the United States could be subject to domestic and foreign taxes and some portion may be subject to governmental restrictions.

### Summary of Cash Flows

*(in thousands)*

| Cash provided by (used in): | Six Months Ended June 30, 2017 | July 1, 2016 |
| --- | ---: | ---: |
| Operating activities | $77,165 | $33,754 |
| Investing activities | (22,263) | (33,282) |
| Financing activities | (61,903) | (46,728) |
| Effect of foreign currency exchange rates on cash and cash equivalents | 1,418 | 368 |
| Net change in cash and cash equivalents | $(5,583) | $(45,888) |

- 40 -

***Operating Activities –*** During the six months ended June 30, 2017, we generated cash of $77.2 million from operations compared to $33.8 million for the six months ended July 1, 2016. This increase was primarily due to higher cash net income ($35.0 million), as well as cash flow provided by working capital accounts ($8.5 million) due to the Company’s strategic initiatives to reduce working capital. Other Non-cash (Gains) Losses reported in cash flows from operating activities increased $11.5 million primarily due to our foreign currency exchange rate losses and cost method investment write-downs recorded during the first six months of 2017, which are non-cash in nature.

***Investing Activities –*** The $11.0 million decrease in net cash used in investing activities was primarily attributable to lower purchases of property, plant, and equipment. Our current expectation is that capital spending for 2017 will be in the range of $50 million to $60 million, of which approximately half is discretionary in nature. We anticipate that cash on hand, cash flows from operations and available borrowing capacity under our Revolving Credit Facility will be sufficient to fund these capital expenditures.

***Financing Activities –*** Net cash used in financing activities for the six months of 2017 was $61.9 million compared to $46.7 million in the comparable 2016 period. Financing activities during the first six months of 2017 included net payments of $70.6 million related to paying down our debt obligations, partially offset by higher proceeds from the exercise of stock options. Financing activities during the six months of 2016 included $76.3 million of cash divested with the Spin-off, which was partially funded by $55.0 million in borrowings incurred under our Revolving Credit Facility, and $6.8 million paid to purchase the remaining non-controlling interests in Nuvectra’s Algostim and PelviStim subsidiaries. See Note 2 “Divestiture” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further description of the Spin-off.

***Capital Structure –*** As of June 30, 2017, our capital structure consists of $1.7 billion of debt outstanding under our Senior Secured Credit Facilities and Senior Notes and 31.4 million shares of common stock outstanding. If necessary, we currently have access to $109.2 million under our Revolving Credit Facility. This amount may vary from period to period based upon our debt and EBITDA levels, which impacts our covenant calculations. If necessary, we are also authorized to issue 100 million shares of common stock and 100 million shares of preferred stock. As of June 30, 2017, our debt service obligations, comprised of principal and interest payments for the second half of 2017, are estimated to be approximately $60 million.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and potential borrowings under the Revolving Credit Facility should be sufficient to meet our working capital and fixed capital requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. Accordingly, we evaluate and consider from time to time various financing alternatives to supplement our financial resources. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all.

***Credit Facilities*** - As of June 30, 2017, we had senior secured credit facilities (the “Senior Secured Credit Facilities”) that consist of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), which had $82 million drawn as of June 30, 2017, (ii) a $347 million term loan A facility (the “TLA Facility”), and (iii) a $913 million term loan B facility (the “TLB Facility”). Additionally, as of June 30, 2017, we had $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 (the “Senior Notes”) outstanding. The Revolving Credit Facility will mature on October 27, 2020, the TLA Facility will mature on October 27, 2021 and the TLB Facility will mature on October 27, 2022. The Senior Secured Credit Facilities include a mandatory prepayment provision customary for credit facilities of its nature.

On March 17, 2017, we amended the Senior Secured Credit Facilities to lower the interest rate on the TLB Facility. The amendment reduces the applicable interest rate margins on our TLB Facility for both base rate and adjusted LIBOR borrowings by 75 basis points. The amendment also includes a prepayment fee of 1.00% in the event of another repricing event (as defined in the Senior Secured Credit Facilities) on or before the six-month anniversary of this amendment. There is no change to maturities or covenants under the Senior Secured Credit Facilities as a result of this repricing amendment.

The Revolving Credit Facility and TLA Facility contain financial covenants requiring (A) a maximum total net leverage ratio (as defined in the agreement governing the Senior Secured Credit Facilities) of 6.25:1.0, subject to step downs beginning in the first fiscal quarter of 2018 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of 2.5:1.0 subject to step ups beginning in the first quarter of 2018. As of June 30, 2017, our total net leverage ratio, calculated in accordance with our credit agreement, was approximately 5.47 to 1.00. For the twelve month period ended June 30, 2017, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our credit agreement, was approximately 3.03 to 1.00.

- 41 -

Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us. As of June 30, 2017, we were in full compliance with the financial covenants described above. However, a significant increase in the LIBOR interest rate above 1% and/or a decline in our operating performance, and in particular our sales and/or adjusted EBITDA, could result in our inability to meet these financial covenants and lead to an event of default if a waiver or amendment could not be obtained from our lenders.

The Revolving Credit Facility is supported by a consortium of thirteen lenders with no lender controlling more than 27% of the facility. As of June 30, 2017, the banks supporting 88% of the Revolving Credit Facility each had an S&P credit rating of at least BBB+ or better, which is considered investment grade. The banks which support the remaining 12% of the Revolving Credit Facility are not currently being rated.

See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further description on the Company’s outstanding debt.

***Non-Guarantor Information –*** For the six months ended June 30, 2017, our subsidiaries that are non-Guarantors under our Senior Secured Credit Facilities represented approximately 33% and 43% of our revenue and EBITDA, respectively. In addition, as of June 30, 2017, our subsidiaries that are non-Guarantors under our Senior Secured Credit Facilities held approximately 28% of our total tangible assets and 3% of our total tangible liabilities. Tangible assets consist of total assets less intangible assets, intercompany receivables, and deferred taxes. Tangible liabilities consist of total liabilities less intercompany payables and deferred taxes.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 16 “Impact of Recently Issued Accounting Standards” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

### Contractual Obligations

There have been no significant changes to our contractual obligations during the six months ended June 30, 2017 as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K. See Note 6 “Debt” and Note 11 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for further discussion on our contractual obligations.

### Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K.

- 42 -

## Market risk

As filed, 541 characters.

Refer to information appearing under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q. Furthermore, a discussion of market risk exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosure about Market Risk, of the Company’s Annual Report on Form 10-K for the year ended December 30, 2016. There have been no material changes in reported market risk since the inclusion of this discussion in the Company’s Annual Report on Form 10-K referenced above.

## Controls and procedures

As filed, 1,403 characters.

a. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of June 30, 2017. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of June 30, 2017, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting

During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 171 characters.

There have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 30, 2016.

Filed Aug 2, 2017.
Source: SEC EDGAR, the filing index for accession 0001114483-17-000020. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
